Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

NCT02269280 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

NCT01048034 ·Status: COMPLETED ·Phase: PHASE2

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

NCT00379912 ·Status: TERMINATED ·Phase: PHASE2

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT00416598 ·Status: COMPLETED ·Phase: PHASE2

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

NCT01333449 ·Status: TERMINATED ·Phase: PHASE2

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

NCT03066648 ·Status: COMPLETED ·Phase: PHASE1

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant

NCT00986804 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

NCT03593915 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

NCT03238248 ·Status: COMPLETED ·Phase: PHASE2

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

NCT07006025 ·Status: RECRUITING ·Phase: PHASE1

A Phase II Study of Maintenance With Azacitidine in MDS Patients

NCT00446303 ·Status: TERMINATED ·Phase: PHASE2

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

NCT00102687 ·Status: COMPLETED ·Phase: PHASE2

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

NCT03502668 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

NCT02775903 ·Status: COMPLETED ·Phase: PHASE2

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

NCT03377725 ·Status: WITHDRAWN ·Phase: PHASE3

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

NCT06297629 ·Status: WITHDRAWN ·Phase: PHASE2

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

NCT03793517 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00004871 ·Status: COMPLETED ·Phase: PHASE1

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

NCT02159040 ·Status: TERMINATED ·Phase: PHASE2

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

NCT02010645 ·Status: TERMINATED ·Phase: PHASE2

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

NCT04857645 ·Status: COMPLETED ·Phase: PHASE2

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

NCT00071799 ·Status: COMPLETED ·Phase: PHASE3

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NCT06284460 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

NCT02121418 ·Status: COMPLETED ·Phase: NA

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

NCT03379727 ·Status: COMPLETED ·Phase: PHASE3